Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
JBIO Jade Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: JBIO
Price (delayed)
$8.61
Market cap
$7.13M
P/E Ratio
N/A
Dividend/share
$2.4
EPS
-$59.5
Enterprise value
-$36.78M
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses
Highlights
JBIO's debt has plunged by 60% YoY and by 25% from the previous quarter
The quick ratio has soared by 54% from the previous quarter
The company's equity fell by 17% YoY
Key stats
What are the main financial stats of JBIO
Market
Valuations
Earnings
Shares outstanding
828,143
Market cap
$7.13M
Enterprise value
-$36.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.1
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$53.37M
Net income
-$48.96M
EBIT
-$48.91M
EBITDA
-$48.65M
Free cash flow
-$49.9M
Per share
Balance sheet
Liquidity
EPS
-$59.5
EPS diluted
-$59.5
Free cash flow per share
-$60.26
Book value per share
$90.62
Revenue per share
$0
TBVPS
$93.62
Total assets
$77.53M
Total liabilities
$2.49M
Debt
$312,000
Equity
$75.05M
Working capital
$74.96M
Debt to equity
0
Current ratio
32.01
Quick ratio
31.53
Net debt/EBITDA
0.9
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-54.3%
Return on equity
-60%
Return on invested capital
-103.6%
Return on capital employed
-65.1%
Return on sales
N/A
Dividend yield
27.87%
DPS
$2.4
Payout ratio
N/A
JBIO stock price
How has the Jade Biosciences stock price performed over time
Intraday
0.35%
1 week
-14.67%
1 month
-90.75%
1 year
-98.71%
YTD
-90.72%
QTD
-90.2%
Financial performance
How have Jade Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$53.37M
Net income
-$48.96M
Gross margin
N/A
Net margin
N/A
The net income rose by 40% year-on-year and by 30% since the previous quarter
JBIO's operating income is up by 40% year-on-year and by 28% since the previous quarter
Price vs fundamentals
How does JBIO's price correlate with its fundamentals
Growth
What is Jade Biosciences's growth rate over time
Valuation
What is Jade Biosciences stock price valuation
P/E
N/A
P/B
0.1
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
JBIO's EPS is up by 44% year-on-year and by 30% since the previous quarter
The price to book (P/B) is 88% less than the last 4 quarters average of 0.8
The company's equity fell by 17% YoY
Efficiency
How efficient is Jade Biosciences business performance
The return on equity has increased by 26% since the previous quarter and by 15% year-on-year
The return on assets is up by 24% since the previous quarter and by 12% year-on-year
The company's return on invested capital rose by 10% QoQ but it fell by 10% YoY
Dividends
What is JBIO's dividend history
DPS
$2.4
Dividend yield
27.87%
Payout ratio
N/A
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Jade Biosciences financials performed over time
The total liabilities has dropped by 84% year-on-year and by 36% since the previous quarter
The quick ratio has soared by 54% from the previous quarter
JBIO's debt is 100% less than its equity
The debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year
JBIO's debt has plunged by 60% YoY and by 25% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.